Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
91 Results for "
Antituberculosis activity
" in MedChemExpress (MCE) Product Catalog:
Products (91)
91 Results for "Antituberculosis activity" in MCE Product Catalog:
Ethionamide hydrochloride (2-Ethylthioisonicotinamide hydrochloride) is an antituberculosis drug with mycobacterial activity. Ethionamide hydrochloride interferes with the bacterial cell wall synthesis process by inhibiting the synthesis of fatty acids in the bacterial cell wall. Ethionamide hydrochloride may have bacteriostatic or bactericidal effects, depending on the concentration of the drug at the site of infection and the susceptibility of the associated microorganisms. Ethionamide hydrochloride combines with NAD+ to form an adduct, thereby exerting its antibacterial effect .
Cat. No.: HY-N12232
CAS No.: 108073-63-8
Category:
Cat. No.: HY-158380
CAS No.: 3125917-86-1
UH-NIP-16 exhibits antimicrobial activity against Mycobacterium tuberculosis, with MIC50 of 1.86 and 3.05 μM, for pathogenic mycobacterial strains H37Rv and CDC1551. UH-NIP-16 synergizes with Streptomycin (HY-B1906), Isoniazid (HY-B0329), Ethambutol (HY-B0535) and Bedaquiline (HY-14881), potentiates their anti-tuberculosis activities .
Cat. No.: HY-155558
CAS No.: 3028076-11-8
Target:
Research Areas:
MptpB-IN-2 (compound 20) is a selective mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with IC50s of 0.64 μM, 4.06 μM and 4.14 μM for MptpB, MptpA and PTP1B, respectively. MptpB-IN-2 shows weak antituberculosis activity with a MIC of 64.9 μM for Mtb H37Rv .
Cat. No.: HY-138958
CAS No.: 192880-96-9
Target:
Research Areas:
HT1171 is a potent and selective inhibitor of mycobacterium tuberculosis proteasome. HT1171 shows strong anti-tuberculosis activity against Mycobacterium tuberculosis H37Rv with an MIC90 of 2 μg/mL and an MIC of 4 μg/mL. When HT1171 concentration is 100 μM, the inhibition rate of human normal hepatocytes L02 is 53.8%. HT1171 can be used in the research of antitubercular agent .
Cat. No.: HY-162508
KSK-104 has potent antibacterial activity against Mycobacterium tuberculosis (MIC=0.78 μM). The role of KSK-104 is mainly involved in the synthesis and recovery pathways of pyridoxal 5'-phosphate (PLP), PLP-dependent enzymes and oxidative stress networks. KSK-104, as a candidate molecule for novel anti-tuberculosis drugs, can be used to develop research against drug-resistant mycobacterium tuberculosis .
Cat. No.: HY-162521
Antibacterial agent 215 (Compound 3b) is an inhibitor for carbonic anhydrase (CA), with Ki of 17.61, 5.14 and 43.74 nM, for hCA I, hCA II and AChE, respectively. Antibacterial agent 215 exhibits anti-tuberculosis, with MIC of 62.5 µg/ml against M. tuberculosis. Antibacterial agent 215 exhibits antifungal activities against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with MICs of 125 µg/ml .
Cat. No.: HY-175262
Target:
Research Areas:
Mtb-IN-12 (Compound 5m) is a dual-target inhibitor that can target the CYP125 (KD: 40 nM; KI: 0.1 μM) and CYP142 (KD: 160 nM; KI: 0.05 μM) enzymes of Mycobacterium tuberculosis. Mtb-IN-12 exhibits good inhibitory activity against both drug-sensitive strains and multidrug-resistant tuberculosis strains, with low toxicity to macrophages. Mtb-IN-12 can be used in the research of anti-tuberculosis drugs .
Cat. No.: HY-12485R
CAS No.: 1257426-19-9
Target:
Research Areas:
TBA-354 (Standard) is the analytical standard of TBA-354 (HY-12485). This product is intended for research and analytical applications. TBA-354 is an orally active, blood-brain barrier permeable anti-tuberculosis compound . TBA-354 acts on replicating, non-replicating and drug-resistant Mycobacterium tuberculosis, retains its activity in the presence of serum proteins or albumin, and induces moderate, reversible neurotoxicity at effective dose levels. TBA-354 can be used in the research of tuberculosis and multidrug-resistant tuberculosis .
Cat. No.: HY-14743A
CAS No.: 2828433-07-2
Synonyms: SCV 07 TFA; Gamma-D-glutamyl-L-tryptophan TFA
Research Areas:
Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .
Cat. No.: HY-14743R
CAS No.: 229305-39-9
Synonyms: SCV 07 (Standard); Gamma-D-glutamyl-L-tryptophan (Standard)
Target:
Research Areas:
Cat. No.: HY-151598
CAS No.: 3031462-75-3
Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC50=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .
Cat. No.: HY-151599
CAS No.: 3031462-62-8
Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC50=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .
Cat. No.: HY-W699983
CAS No.: 74362-46-2
Synonyms: Glyoxaline-15N2; 1,3-Diaza-2,4-cyclopentadiene-15N2
Cat. No.: HY-189379
Target:
Research Areas:
Antituberculosis agent-18 is an anti-tuberculosis compound that inhibits the growth of Mycobacterium tuberculosis. Antituberculosis agent-18 exhibits moderate antimycobacterial activity against Mycobacterium tuberculosis H37Rv. Antituberculosis agent-18 can be used for research on tuberculosis .
Cat. No.: HY-179444
Target:
Research Areas:
Antituberculosis agent-17 (compound 21) is a potent and selective antituberculosis agent. Antituberculosis agent-17 displays excellent anti-Tuberculosis (TB) activity against H37Rv, MDR and XDR strains of TB (MIC = 0.2-0.78 μM). Antituberculosis agent-17 exhibits selectivity for Mycobacterium tuberculosis over selected non-TB forming mycobacteria and bacteria. Antituberculosis agent-17 can be used for TB research .
Cat. No.: HY-181771
IDD-AN-A1 is a potent Mycobacterium tuberculosis (Mtb) isocitrate lyase (ICL) inhibitor with an IC50 of 7 μg/mL. IDD-AN-A1 shows additive and synergistic activity with anti-tuberculosis agents. , respectively.IDD-AN-A1 exhibits potent anti-tuberculosis activity. IDD-AN-A1 can be used for the research of tuberculosis .
Cat. No.: HY-N19235
CAS No.: 74134-77-3
Category:
Target:
Cat. No.: HY-L142
159 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.
Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.
MCE supplies a unique collection of 159 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development
Cat. No.: HY-179383
DprE1-IN-14 (Compound 77) is a DprE1 inhibitor, with an IC50 value of 2.5 nM for M. tb. DprE1-IN-14 exhibits anti-tuberculosis activity, with an MIC₉₀ of 0.3 μM for the M. tb mc26230 strain. DprE1-IN-14 mainly shows bacteriostatic activity, demonstrating a time-dependent bactericidal effect at 10-fold MIC concentrations. DprE1-IN-14 can be used in anti-tuberculosis research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
